---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-281988"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:08:40.380604+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# UroGen Q3 JELMYTO revenue up 41% to $16.1M; net loss narrows to $25.8M

## Summary
- JELMYTO net product revenue $16.1M (+41% YoY); operating loss improved to $18.1M from $23.4M.
- Net loss $25.8M ($1.13/share) vs $30.2M ($1.35/share) in Q3 2021; cash, cash equivalents and marketable securities $95.9M.
- ENVISION Phase 3 trial for UGN-102 enrollment completion expected as soon as end of Nov 2022; NDA submission anticipated H1 2024.
- FDA authorized extension of JELMYTO in-use period from 8 to 96 hours following reconstitution.
- Appointed Dr. Leana S. Wen and Dan Wildman to the Board of Directors.

## SEC filing metadata
- accession: 0001193125-22-281988
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312522281988/0001193125-22-281988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312522281988/d405971d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-281988
- JSON: https://secwatch.observer/filing/0001193125-22-281988.json
- Plain text: https://secwatch.observer/filing/0001193125-22-281988.txt

## Key facts
- Earnings Releases
  UroGen Pharma Ltd. reported the third quarter ended September 30, 2022 results: revenue $16.1 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $16.1 million
  - Result: reported results
  source text: invasive bladder cancer (LG-IR-NMIBC) expected as soon as the end of November 2022; NDA submission anticipated in first half of 2024 • Reported JELMYTO ® net product revenue of $16.1 million, an increase of 41% from the same period last year • FDA authorized extension of the in-use period for JELMYTO ® admixture from 8 to 96 hours following reconstitution further
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312522281988/0001193125-22-281988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.